"Designing Growth Strategies is in our DNA"

Antibacterial Drugs Market Size, Share & Industry Analysis, By Class (Lactams, Tetracycline, Quinolones, Macrolides, Sulphonamide, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Regional Forecast, 2024-2032

Region :Global | Report ID: FBI104472 | Status : Ongoing

 

KEY MARKET INSIGHTS

Antibacterial drugs are the compounds that are used against the bacteria which work by either inhibiting their growth of by killing them. Many classes of antibacterial drugs have been developed and are available according to their chemical nature, range of activity, and method of action. An increase in the incidences of infectious diseases resulting in the rise in the demand for antibacterial drugs is driving the market growth. Factors such as a rise in incidences of infectious diseases, growing healthcare spending, modernization of the healthacre infrastructure, and improving diagnosis rate are the major factor driving the growth of the market. According to the World Health Organization (WHO), more than 30 new infections have been estimated to have emerged in the last two decades, which threaten the health of millions of individuals.


Moreover, an increase in the frequencies of zoonotic diseases is also propelling the growth of the market. According to the Centers for Disease Control (CDC) in 2017, estimated that 3/4th of new or emergent infectious diseases in society come from animals. In addition, the growth of the market is also expected to be boosted by the multidrug-resistant bacteria known as superbugs. The overall growth of the market is rising due to factors such as significant investments in R&D activities, a rise in the incidences of infectious diseases, and zoonotic disease outbreaks.

However, stringent regulatory guidelines, resistance to the antibacterial drugs developed by the bacteria,  and high cost of drug approval are projected to obstruct the market growth.

Key Market Driver -

Rise in incidences of infectious diseases and zoonotic diseases.

Key Market Restraint -

Stringent regulatory guidelines and high cost of drug approval.


Market Segmentation:


The global antibacterial drugs market can be segmented on the basis of class, route of administration, distribution channel, and region. Based on the class, the market can be segmented into B – lactams, tetracycline, quinolones, macrolides, sulfonamide, and others. Based on the route of administration, the market can be segmented into oral and parenteral. Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies

Geographically, the antibacterial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:


The major companies in the global antibacterial drugs report include Shionogi & Co., Ltd., Bayer AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Novartis AG, Allergan, and other prominent players.

Key Insights:



  • New Antibacterial Drug Launch

  • Disease Outbreaks in Key Countries

  • Infectious Diseases Incidences for Key Countries

  • Recent Antibacterial Drugs Research & Development Activities

  • Key Industry Developments - Mergers, Acquisitions, and Partnerships


Regional Analysis:


Geographically, the global antibacterial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically, North America is expected to account for the significant market share of the market, and it is also anticipated to retain its superiority throughout the forecast period. The region will prove to be a profitable market for antibacterial drug manufacturers due to enormous R&D expenditure and developing treatment solutions for superbugs. Europe's market is anticipated to holds the second-largest share in the market. However, Asia-Pacific possesses the high potential for growth of the market due to the rise in the geriatric population, an increase in the incidences of infectious & zoonotic diseases, growing R&D activities in this region as well as growing demand for improved antibacterial drugs at an affordable cost in the region. Latin America and the Middle East & Africa are increasing steadily in the market.

To gain extensive insights into the market, Request for Customization


Segmentation


























 ATTRIBUTE

  DETAILS

By Class



  • B – Lactams

  • Tetracycline

  • Quinolones

  • Macrolides

  • Sulphonamide

  • Others



By Route of Administration



  • Oral

  • Parenteral



By Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies



By Geography



  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)



Antibacterial Drug Market Industry Developments



  • In October 2019, GlaxoSmithKline plc announced the phase III clinical programme investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection and urogenital gonorrhea.

  • In November 2019, Allergan plc announced the approval of Qualified Infectious Disease Product and Fast Track Designation by U.S. Food and Drug Administration (FDA) for ATM-AVI (aztreonam and avibactam), for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP).

  • In November 2019, – Shionogi & Co., Ltd. announced the approval of FETROJA (cefiderocol) by the U.S. Food and Drug Administration (FDA) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

iqvia
Fresenius
3M
Ansell
Ipsos

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X